Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer

Status Completed

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have metastatic kidney cancer.

Clinical Trial Description

OBJECTIVES: I. Evaluate the efficacy of arsenic trioxide in patients with metastatic renal cell cancer. II. Determine the safety of this regimen in this patient population.

OUTLINE: Patients receive arsenic trioxide IV over 1-4 hours daily for 5 days. Treatment continues every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for at least 1 month.

PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19 months. ;

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00005069
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase	Phase 2
Start date	January 2000
Completion date	July 2001

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00541008` - Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer	Phase 2
Completed	`NCT03520231` - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases	Phase 2
Recruiting	`NCT04623502` - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	N/A
Terminated	`NCT00788125` - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT03634540` - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)	Phase 2
Completed	`NCT04534309` - Behavioral Weight Loss Program for Cancer Survivors in Maryland	N/A
Active, not recruiting	`NCT01529658` - Renal Hypothermia During Partial Nephrectomy	N/A
Completed	`NCT01048892` - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	Phase 1
Withdrawn	`NCT00769990` - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases	Phase 1/Phase 2
Completed	`NCT00790569` - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking	N/A
Terminated	`NCT00896467` - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy	N/A
Recruiting	`NCT00301990` - Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer	Phase 2
Completed	`NCT00098943` - NGR-TNF in Treating Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00467077` - Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer	Phase 2
Terminated	`NCT00089102` - Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer	Phase 2
Terminated	`NCT00899860` - Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer	N/A
Completed	`NCT00021021` - RPI.4610 in Treating Patients With Metastatic Kidney Cancer	Phase 2
Completed	`NCT00006968` - Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer	Phase 1/Phase 2
Completed	`NCT00006022` - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer	Phase 1